Neoadjuvant therapy combined with anti- HER2 therapy is an effective treatment option for HER2-positive breast cancer (based on IHC defined as HER2-amplified IHC 3+ or IHC 2+ and ISH amplification). This evidence concerns the gene ERBB2 and breast cancer.